Which endpoint to choose ? (in phase II sarcoma clinical trials) George D. Demetri, MD Dana-Farber / Harvard Cancer Center, Boston Mass. USA for Robert.
Getting a Clinical Research Protocol Started: The CTSA Response
New Targets and New Treatments in Melanoma
New Targets and New Treatments in Melanoma Brendan D. Curti, MD Director, Melanoma Program Director Biotherapy Program Providence Cancer Center Earle A.
1 Oncologic Drugs Advisory Committee on MTP for Osteosarcoma IDM Pharma, Inc. May 9, 2007 Silver Spring, MD IDM Pharma, Inc. May 9, 2007 Silver Spring,
Which endpoint to choose ? (in phase II sarcoma clinical trials)
